Partners
The right cargo is only the beginning
Nucleic acid medicine programs often stall when delivery, formulation, and development planning are handled in isolation. As an integrated LNP delivery partner, Mirai brings these decisions together earlier, helping teams advance cell-specific and extrahepatic LNP delivery with translation in mind.
For partners who need delivery to change the equation
-
Cargo is compelling but delivery remains the gating variable
-
Program requires cell-specific or beyond-liver delivery
-
Need to reduce handoff risk across design, delivery, and development
-
Building internally would be too slow or capital-intensive
-
Standard vendor models are too narrow for the program’s complexity
How companies partner with Mirai
We can help advance your asset with translation in mind from any stage.
-
01 Cargo-ready vehicles
NHP-proven vehicles, optimized for your needs and designed for development and manufacturing success.
-
02 Emerging access vehicles
Advance your cargo with vehicles that have demonstrated access to high-value extrahepatic targets.
-
03 Novel LNP discovery
Pioneer access to novel tissue frontiers together
We co-create alongside biotechs, optimizing for end success at every step
Mirai meets partners where they are — adapting to different disease areas, program stages, and cargo types while acting as an extension of your team throughout the development journey.
The Mirai partnership journey
-
Align
Align on your program goals, challenges, and starting point.
-
Strategize
Build a customized development strategy based on your disease area, program maturity, and cargo type.
-
Engineer
Mirai formulates and optimizes your therapeutic using our delivery platform, proprietary technologies, and AI-driven approaches.
-
Evaluate
Mirai generates the data needed to assess performance and guide critical development decisions.
-
Advance
Together, we translate insights into next steps and position your program for continued progress to the clinic.
Targeted delivery with development built in
-
1
Expand target access
We advance cell-specific and extrahepatic delivery across T cells, adipocytes, HSCs, B cells, NK cells, macrophages, endothelial cells, lung, pancreas, and liver.
-
2
Optimize performance
We use AI/ML-guided design and proprietary in vivo data to improve potency, selectivity, liver detargeting, tolerability, and overall delivery performance.
-
3
Reduce handoff risk
We integrate cargo design, LNP optimization, process development, analytics, and manufacturing planning from the start to support a more seamless path forward.
Turn delivery into development advantage
Explore a targeted LNP delivery partnership built around your cargo, target, and development goals.